Beijing StarMab BioMed Technology
Latest round
- Series A
Last raised
- Feb 2024
Total raised
- $16M
Investors
- 5
About Beijing StarMab BioMed Technology
Founded in 2019 and based in Beijing, China, Beijing StarMab BioMed Technology Ltd is a biotech company that focuses on the development of antibody drugs. Dr. Yanbin Liang, the founder of the company, has worked for Eli Lilly and Allergan in the United States. The company has research and development bases in Beijing and California. In 2022, the firm completed in vitro and animal efficacy POC, monkey PK and toxicity studies. In 2023, the company's SM3321 injection received clinical approval from the NMPA. The company's main products include SM3321, SM1542 and SM009. The unique binding site of SM3321 drug can strongly target tumor cells, activate immune cell function, and reduce non-specific toxic reactions. The company's products are used in oncology, inflammation and neurodegenerative diseases.
Who invested in Beijing StarMab BioMed Technology
5 investors across 2 rounds
See all investors in Beijing StarMab BioMed Technology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Beijing StarMab BioMed Technology
Who invested in Beijing StarMab BioMed Technology?
Beijing StarMab BioMed Technology has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Beijing StarMab BioMed Technology raised?
Beijing StarMab BioMed Technology has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Beijing StarMab BioMed Technology last raise money?
Beijing StarMab BioMed Technology's most recent round on record is a Series A, in Feb 2024.
What does Beijing StarMab BioMed Technology do?
Founded in 2019 and based in Beijing, China, Beijing StarMab BioMed Technology Ltd is a biotech company that focuses on the development of antibody drugs.
Where is Beijing StarMab BioMed Technology headquartered?
Beijing StarMab BioMed Technology is headquartered in Beijing, China.
Which VCs invest in companies like Beijing StarMab BioMed Technology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Beijing StarMab BioMed Technology's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Beijing StarMab BioMed Technology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.